BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

Alzheimer’s disease is a type of dementia, and there are more than 7 million Americans living with it. According to the ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

HEALTH campaigners fear the country is sleepwalking into a dementia care crisis. Alzheimer Scotland bosses have launched a ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the forecast period. This growth is largely driven by the increasing incidence ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.